 NEW YORK--BUSINESS WIRE--CM Life Sciences Nasdaq: CMLF, a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, has filed its definitive proxy statement with the Securities and Exchange Commission the SEC in connection with the previously announced proposed business combination with Sema4. The definitive proxy statement contains important information about the proposed business combination contemplated by the Agreement and 